Entera Bio Announces Presentations Of New Data Supporting Its Oral Peptide Pipeline At The Annual Endochrine Society Meeting On June 13-16

Entera Bio Ltd.

Entera Bio Ltd.

ENTX

0.00
  • Abstract Title: Transforming Anabolic Treatments for Osteoporosis: New Clinical Data Supports a Single EB613 Tablet [Oral PTH(1-34)] as the Final Candidate for a Phase 3 Study
    Session Title: Late-Breaking Oral Abstract/Rapid-Fire II
    Session Date/Time: Sunday, June 14, 2026, 3:30 – 4:15 PM CT
  • Abstract Title: Pre-Clinical Results for EB612: First-in-Class Oral Long-Acting PTH(1-34) Analog as Hormone Replacement Tablet for Patients with Hypoparathyroidism
    Session Date/Time: Monday, June 15, 2026, 12:00 – 1:30 PM CT
  • Abstract Title: EB618, First-in-Class Oral Tablet of Dual GLP-1/Glucagon Receptor Agonist for Patients with Obesity and Metabolic Disorders: Results from PK-PD Study in Non-Human Primates

    Session Date/Time: Saturday, June 13, 2026, 12:15 – 1:45 PM CT
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.